Published by Global Banking & Finance Review®
Posted on December 31, 2024
1 min readLast updated: January 27, 2026
Add as preferred source on Google
UK's MHRA approves Merck's sotatercept for treating pulmonary arterial hypertension, a rare lung condition. The therapy, known as Winrevair, aims to improve exercise capacity in affected adults.
(Reuters) - UK's Medicines and Healthcare products Regulatory Agency (MHRA) said on Tuesday it had approved Merck's therapy to treat a rare lung condition called pulmonary arterial hypertension.
The therapy, sotatercept, received approval in the United States in March 2024 and is sold under the brand name Winrevair.
Patients with pulmonary arterial hypertension have high blood pressure in the vessels that supply the lungs. It is a rare and serious condition that can damage the right side of the heart.
The MHRA said the treatment can be used in combination with other medicines in adults with moderate or marked limitations of physical activity to help improve their exercise capacity.
(Reporting by Bhanvi Satija in Bengaluru; Editing by Anil D'Silva)
The main topic is the UK approval of Merck's therapy for pulmonary arterial hypertension, a rare lung condition.
Pulmonary arterial hypertension is a rare condition characterized by high blood pressure in the vessels supplying the lungs, potentially damaging the heart.
Merck's therapy for pulmonary arterial hypertension is sold under the brand name Winrevair.
Explore more articles in the Finance category
